[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JP2009502777A5 - - Google Patents

Download PDF

Info

Publication number
JP2009502777A5
JP2009502777A5 JP2008522170A JP2008522170A JP2009502777A5 JP 2009502777 A5 JP2009502777 A5 JP 2009502777A5 JP 2008522170 A JP2008522170 A JP 2008522170A JP 2008522170 A JP2008522170 A JP 2008522170A JP 2009502777 A5 JP2009502777 A5 JP 2009502777A5
Authority
JP
Japan
Prior art keywords
tumors
compound
group
compound according
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008522170A
Other languages
English (en)
Other versions
JP2009502777A (ja
JP5312026B2 (ja
Filing date
Publication date
Priority claimed from IT000389A external-priority patent/ITRM20050389A1/it
Application filed filed Critical
Publication of JP2009502777A publication Critical patent/JP2009502777A/ja
Publication of JP2009502777A5 publication Critical patent/JP2009502777A5/ja
Application granted granted Critical
Publication of JP5312026B2 publication Critical patent/JP5312026B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (13)

  1. 一般式(I)の化合物
    Figure 2009502777

    [式中、
    及びRは、同一でも異なってもよく、−H又は1〜6個の炭素原子を有する直鎖又は分枝アルキル基を含む群から選択されるか、一緒になって5個又は6個の原子の芳香族又は脂肪族環を形成しており;
    Y及びZは、同一でも異なってもよく、−H、−OH、−COOH、−OR、−CH(OR)COOHを含む群から選択され、ここでRは、H、フェニル、ベンジル、−CF又は−CFCF、ビニル、アリル及び1〜6個の炭素原子を有する直鎖又は分枝アルキル基から選択される]。
  2. 一般式(Ia)の化合物
    Figure 2009502777

    [式中、
    及びRは、同一でも異なってもよく、−H又は1〜6個の炭素原子を有する直鎖又は分枝アルキル基を含む群から選択され;
    Y及びZは、同一でも異なってもよく、−H、−OH、−COOH、−OR、−CH(OR)COOHを含む群から選択され、ここでRは、−H及び1〜6個の炭素原子を有する直鎖又は分枝アルキル基から選択される]である、請求項1に記載の化合物。
  3. 1〜6個の炭素原子を有する直鎖又は分枝アルキル基が、−CH、−CHCH、−CH(CH、−CHCHCH、−C2n−1 (nは炭素の数である)から選択される、請求項1又は請求項2に記載の化合物。
  4. YがH又は−COOHである、請求項1から3までのいずれか一項に記載の化合物。
  5. Zが−CH(OR)COOHである、請求項1から4までのいずれか一項に記載の化合物。
  6. −CH CH −CH 又は−Hである、請求項1から5までのいずれか一項に記載の化合物。
  7. 化合物が、
    Figure 2009502777

    Figure 2009502777

    Figure 2009502777

    Figure 2009502777

    Figure 2009502777

    Figure 2009502777

    Figure 2009502777

    Figure 2009502777

    を含む群から選択される、請求項1から6までのいずれか一項に記載の化合物。
  8. 鏡像異性的に純粋なR型又はS型をしている、請求項1からまでのいずれか一項に記載の化合物。
  9. ±)−2−ヒドロキシ−2−(3’−アミノフェニル)酢酸
    (±)−2−ヒドロキシ−2−(4’−アミノフェニル)酢酸
    (±)−2−ヒドロキシ−3−(4’−アミノフェニル)プロピオン酸
    (±)−2−メトキシ−3−(3’−アミノフェニル)プロピオン酸
    (±)−2−メトキシ−3−(4’−アミノフェニル)プロピオン酸
    を含む群から選択される化合物を含む、癌性腫瘍又は慢性炎症性疾患の治療の為の医薬品。
  10. 有効成分として請求項1からまでのいずれか一項に記載の1つ又は複数の化合物を1つ又は複数の薬学的に許容できる賦形剤又は補助剤と組合せて含む薬剤組成物。
  11. PPARγ受容体及びEGF受容体を発現する腫瘍の予防及び治療のための請求項1からまでのいずれか一項に記載の化合物を含み、腫瘍が、食道の腫瘍、胃の腫瘍、膵臓の腫瘍、結腸の腫瘍、前立腺の腫瘍、乳房の腫瘍、子宮及び付属器の腫瘍、腎臓の腫瘍並びに肺の腫瘍を含む群から選択される、薬剤組成物。
  12. クローン病及び潰瘍性結腸大腸炎を含む慢性炎症性疾患治療用の請求項1からまでのいずれか一項に記載の化合物を含む医薬品
  13. 化合物が、1つの鏡像異性体が任意の割合で他を超えている混合物中にある、請求項9、11又は12に記載の医薬品
JP2008522170A 2005-07-22 2006-07-24 Ppar受容体及びegf受容体に特異的な化合物及びそれらの塩並びに医療分野におけるそれらの使用 Active JP5312026B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000389A ITRM20050389A1 (it) 2005-07-22 2005-07-22 Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM2005A000389 2005-07-22
PCT/IE2006/000078 WO2007010516A2 (en) 2005-07-22 2006-07-24 Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field

Publications (3)

Publication Number Publication Date
JP2009502777A JP2009502777A (ja) 2009-01-29
JP2009502777A5 true JP2009502777A5 (ja) 2009-10-01
JP5312026B2 JP5312026B2 (ja) 2013-10-09

Family

ID=37579831

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008522170A Active JP5312026B2 (ja) 2005-07-22 2006-07-24 Ppar受容体及びegf受容体に特異的な化合物及びそれらの塩並びに医療分野におけるそれらの使用

Country Status (23)

Country Link
US (6) US8153841B2 (ja)
EP (1) EP1910270B3 (ja)
JP (1) JP5312026B2 (ja)
KR (1) KR101317519B1 (ja)
CN (2) CN102020577B (ja)
AU (1) AU2006271165C1 (ja)
CA (1) CA2616146C (ja)
CY (1) CY1114294T1 (ja)
DK (1) DK1910270T6 (ja)
EA (2) EA014665B3 (ja)
ES (1) ES2421260T7 (ja)
HR (1) HRP20130549T4 (ja)
IL (2) IL188878A (ja)
IT (1) ITRM20050389A1 (ja)
MX (1) MX366596B (ja)
NO (1) NO340680B1 (ja)
NZ (2) NZ566045A (ja)
PL (1) PL1910270T6 (ja)
PT (1) PT1910270E (ja)
SI (1) SI1910270T1 (ja)
UA (1) UA100359C2 (ja)
WO (1) WO2007010516A2 (ja)
ZA (2) ZA200801671B (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
IE20070129A1 (en) 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
ITMI20072429A1 (it) 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
UA107562C2 (uk) * 2008-12-05 2015-01-26 Спосіб лікування псоріазу
CN102316932B (zh) * 2009-02-16 2014-07-09 朱利亚尼国际有限公司 治疗与毛发相关的病况的方法
EP2578573A4 (en) 2010-05-24 2014-08-06 Toa Eiyo Ltd CONDENSATE IMIDAZOLE DERIVATIVE
CN104254327A (zh) 2012-02-09 2014-12-31 诺格拉制药有限公司 治疗纤维化的方法
US9682050B2 (en) 2012-04-18 2017-06-20 Nogra Pharma Limited Methods of treating lactose intolerance
FR2996545B1 (fr) 2012-10-08 2016-03-25 Ecole Polytech Procede microfluidique de traitement et d'analyse d'une solution contenant un materiel biologique, et circuit microfluidique correspondant.
US10257875B2 (en) * 2014-03-20 2019-04-09 Kyocera Corporation User terminal, communication control method, and base station
WO2017093444A1 (en) * 2015-12-01 2017-06-08 Nogra Pharma Limited Compositions for oral administration in the treatment of inflammatory bowel disease
EP3914227A1 (en) 2019-01-25 2021-12-01 Nogra Pharma Limited Compositions for use in preventing acne
BR112021015609A2 (pt) * 2019-02-08 2021-10-05 Nogra Pharma Limited Processo de fabricação de ácido 3-(4?-aminofenil)-2-metoxipropiônico, e análogos e intermediários do mesmo

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB767788A (en) 1953-12-28 1957-02-06 Schering Corp Polyiodinated phenyl fatty acid compounds and process for their manufacture
US3211610A (en) * 1961-09-29 1965-10-12 Merck & Co Inc Benzoic acid ester derivatives for treating coccidiosis and method of using same
US3444232A (en) * 1966-05-18 1969-05-13 Squibb & Sons Inc O-alkyl or phenylalkyl benzohydroxamic acids
GB1359560A (en) 1972-02-25 1974-07-10 Merck & Co Inc Preparation of pyrrylsalicylic acid
US4036951A (en) * 1973-03-12 1977-07-19 Synergistics, Inc. Ultra-violet filtration with certain aminosalicylic acid esters
FR2440353A1 (fr) * 1978-11-03 1980-05-30 Science Union & Cie Nouveaux arylethanols, leurs procedes d'obtention et leur emploi comme medicament
US4348223A (en) * 1980-12-05 1982-09-07 Ppg Industries, Inc. N-Alkyl-N-[3-(alkoxyalkyl)phenyl]-2-haloacetamide herbicides
DE3164618D1 (en) 1980-12-22 1984-08-09 Schering Ag 3-substituted 2,4,6-trihalogenobenzamides and their salts, their preparation and their use as substitutes for natural sweetening agents, and sweeteners containing them
JPS58194814A (ja) 1982-05-11 1983-11-12 Nippon Shinyaku Co Ltd 免疫調節作用を有する薬剤
IL69282A (en) 1982-09-02 1988-06-30 Euro Celtique Sa Method for the carboxylation of potassium phenoxide with carbon dioxide
DE3786452T2 (de) * 1987-02-05 1993-10-21 Kureha Chemical Ind Co Ltd Benzylether-Verbindungen und Verfahren zu ihrer Herstellung.
NZ224087A (en) 1987-04-01 1990-08-28 Dak Lab As Topical pharmaceutical compositions containing 4- or 5- amino salicylic acid or a functional derivative thereof
DE68919009T2 (de) 1988-05-05 1995-02-23 Tillotts Pharma Ag Verwendung von 5-Amino-salicylsäure für die Behandlung von Hautkrankheiten.
CA2090220C (en) 1990-10-22 2003-07-08 Thomas Julius Borody Treatment of non-inflammatory and non-infectious bowel disorders
US5519014A (en) * 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
US5262549A (en) * 1991-05-30 1993-11-16 Polaroid Corporation Benzpyrylium dyes, and processes for their preparation and use
US5302751A (en) 1992-01-21 1994-04-12 Ethyl Corporation Profen resolution
ATE214608T1 (de) 1992-06-30 2002-04-15 Howard K Shapiro Verwendung einer kombination bestehend aus einem aminderivat oder aminverwandten derivat der benzoesäure und einem amino-polysaccharide zur herstellung eines medikaments fuer die behandlung von entzündlichen erkrankungen
US5594151A (en) * 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
WO1995031194A1 (en) 1994-05-11 1995-11-23 Shapiro Howard K Compositions for treatment of chronic inflammatory diseases
US5594015A (en) 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
EP0817631A2 (en) 1995-03-28 1998-01-14 Janssen Pharmaceutica N.V. Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9617001D0 (en) 1996-08-13 1996-09-25 Tillotts Pharma Ag Oral composition
DE19647582A1 (de) * 1996-11-18 1998-05-20 Hoechst Ag Verfahren zur Herstellung von aromatischen Olefinen mittels Katalyse durch Palladaphosphacyclobutane
WO1998043081A1 (en) 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Treatment of gastrointestinal disease with ppar modulators
AU8588798A (en) * 1997-07-25 1999-02-16 Institut Pasteur Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
AU9002798A (en) * 1997-09-19 1999-04-12 Ono Pharmaceutical Co. Ltd. Fused or nonfused benzene compounds
FR2773075B1 (fr) 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6114382A (en) 1998-11-11 2000-09-05 Moretti; Itagiba G. Methods for treating inflammatory bowel disease
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
FR2791671B1 (fr) 1999-04-01 2001-05-11 Oreal Nouveaux composes derives d'esters d'acide benzoique, composition les comprenant et utilisation
GB9908647D0 (en) 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
US20040034067A1 (en) * 1999-04-15 2004-02-19 Macphee Colin Houston Novel method of treatment
GB9914371D0 (en) 1999-06-18 1999-08-18 Smithkline Beecham Plc Novel compounds
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
CA2656216C (en) 2000-04-19 2012-01-24 Neurotech Co., Ltd. Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
US7049342B2 (en) 2000-05-29 2006-05-23 Kyorin Pharmaceutical Co., Ltd. Substituted phenylpropionic acid derivatives
ATE407919T1 (de) * 2000-05-29 2008-09-15 Kyorin Seiyaku Kk Substituierte phenylpropionsäure-derivate
AU2001285311B2 (en) * 2000-08-29 2005-09-15 Biocon, Ltd Immunoregulatory compounds, derivatives thereof and their use
EP1348698A4 (en) 2000-12-05 2005-01-19 Kyorin Seiyaku Kk SUBSTITUTED CARBOXYLENE DERIVATIVES
FR2822955B1 (fr) 2001-03-27 2003-10-03 Chru Lille Methode de diagnostic de maladies inflammatoires chroniques de l'intestin
WO2002085123A1 (en) 2001-04-18 2002-10-31 Merck & Co., Inc. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
CA2354921A1 (en) 2001-05-24 2002-11-24 Yasuo Konishi Drug evolution: drug design at hot spots
JP2005505617A (ja) * 2001-10-16 2005-02-24 ドクター・レディーズ・ラボラトリーズ・リミテッド 新規のβ−フェニル−α−オキシ置換型プロピオニック誘導体、その製造方法および薬剤的に重要な化合物の製造におけるその使用
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
US20030113815A1 (en) * 2001-12-19 2003-06-19 Pfizer Inc. Canine peroxisome proliferator activated receptor gamma
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20040115127A1 (en) * 2002-04-12 2004-06-17 Wright Samuel D. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
US20060159648A1 (en) 2003-02-17 2006-07-20 Davis Adrian F Novel therapeutic method and compositions for topical administration
GB0303609D0 (en) 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
EP1607103A1 (en) 2003-03-20 2005-12-21 Eisai Co., Ltd. Concomitant drug as therapeutic agent for inflammatory bowel disease
US7589232B2 (en) 2003-07-21 2009-09-15 Laboratories Serono S.A. Alkynyl aryl carboxamides
GB2422782A (en) 2003-10-21 2006-08-09 Inspire Pharmaceuticals Inc Non-nucleotide compositions and method for treating pain
EP1680397A2 (en) * 2003-10-28 2006-07-19 Dr. Reddy's Laboratories Ltd. Novel compounds and their use as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
JP2007513173A (ja) 2003-12-03 2007-05-24 スミスクライン・ビーチャム・コーポレイション ロシグリタゾンを用いる乾癬の治療
AU2004314731B2 (en) 2004-01-20 2011-07-07 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
WO2005084658A1 (en) 2004-03-04 2005-09-15 Arakis Ltd. Derivatives of actarit and their therapeutic use
US20060286046A1 (en) 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
US20060270635A1 (en) * 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
DE102005061472A1 (de) * 2005-12-22 2007-07-05 Saltigo Gmbh Verfahren zur Herstellung von enantiomerenangereicherten 2-Alkoxy-3-phenylpropionsäuren
WO2007096148A1 (en) 2006-02-23 2007-08-30 Lipid Nutrition B.V. Immunoregulation
US7645801B2 (en) 2007-01-29 2010-01-12 Alaven Pharmaceutical Llc Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
IE20070129A1 (en) 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
WO2009025854A1 (en) 2007-08-22 2009-02-26 Burnham Institute For Medical Research Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
ITMI20072429A1 (it) 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
US8030520B2 (en) 2008-03-31 2011-10-04 Saltigo Gmbh Process for preparing organic compounds by a transition metal-catalysed cross-coupling reaction of an aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halide
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
CN102316932B (zh) 2009-02-16 2014-07-09 朱利亚尼国际有限公司 治疗与毛发相关的病况的方法
EP2298321A1 (en) 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
US20140256661A1 (en) 2011-07-15 2014-09-11 David Nigel Armstrong Pharmaceutical compositions for rectal administration
WO2013064153A1 (en) 2011-10-31 2013-05-10 Claus Selch Larsen Prodrugs of non- steroid anti - inflammatory agents (nsaids)
CN104254327A (zh) 2012-02-09 2014-12-31 诺格拉制药有限公司 治疗纤维化的方法
US9682050B2 (en) 2012-04-18 2017-06-20 Nogra Pharma Limited Methods of treating lactose intolerance
EP2861563B1 (en) 2012-06-01 2017-07-12 Nogra Pharma Limited Bicyclic heterocycles capable of modulating t-cell responses, and methods of using same
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
EA201590551A1 (ru) 2012-09-13 2015-06-30 Ногра Фарма Лимитед Способы ингибирования роста волос
EP2895160B1 (en) 2012-09-13 2018-05-30 Nogra Pharma Limited Methods of treating hair related conditions
US20180193361A1 (en) 2015-04-02 2018-07-12 University Health Network Gut anti-inflammatory agents for regulation of high blood glucose levels
KR102722949B1 (ko) 2015-06-15 2024-10-28 엔엠디 파마 에이/에스 신경근 장애의 치료에 사용하기 위한 화합물

Similar Documents

Publication Publication Date Title
JP2009502777A5 (ja)
JP6986022B2 (ja) Fxrアゴニストを使用するための方法
CN110105200B (zh) 用于治疗纤维化的经取代的芳族化合物及相关方法
JP2010532768A5 (ja)
JP2009242409A5 (ja)
JP2009502775A5 (ja)
JP2010540555A5 (ja)
JP2010500293A5 (ja)
JP2010522710A5 (ja)
JP2010077141A5 (ja)
JP2011518202A5 (ja)
JP2016534063A5 (ja)
JP2013519632A5 (ja)
JP2010523476A5 (ja)
JP2009530398A5 (ja)
JP2011051993A5 (ja)
JP2004514663A5 (ja)
JP2010530881A5 (ja)
JP2012525393A5 (ja)
JP2010090149A5 (ja)
NZ586751A (en) Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function
JP2008542386A5 (ja)
JP2011502174A5 (ja)
JP2015535831A5 (ja)
JP2013511556A5 (ja)